Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: juvenile idiopathic arthritis

Juvenile-Onset Arthritis Bodes Worse Pregnancy Outcomes

David Douglas  |  

NEW YORK (Reuters Health)—Women with a diagnosis of juvenile idiopathic arthritis (JIA) are at increased risk of pregnancy complications, according to Swedish researchers. As Dr. Katarina Remaeus told Reuters Health by email, “In our cohort study . . . we found an association with adverse pregnancy outcomes including preterm birth, induction of labor and delivery…

Immune System Targeted for Research into New Rheumatoid Arthritis Treatments

  |  

WASHINGTON, D.C.—Researchers at the 2016 ACR/ARHP Annual Meeting discussed how they are exploring the immune system in search of groundwork for new rheumatoid arthritis (RA) treatments. The new avenues, supported by the Rheumatology Research Foundation, involve T cell adhesion, new understanding of the role of macrophages and insights into the way IgG glycans function. T…

Pediatric Rheumatology Research Highlights Successful Approaches to Manage Juvenile Rheumatic Diseases

  |  

WASHINGTON, D.C.—Patients with juvenile rheumatic diseases are thriving in an era of highly effective therapies, successful self-management strategies, better understanding of genetic links to autoimmunity risk and improved efforts to listen to and engage with these young patients. That bright picture for young people with arthritis was presented by pediatrics at the ACR/ARHP Concurrent Abstract…

The Future of Pediatric Rheumatology Grounded in Evolution of Childhood Arthritis and Rheumatology Research Alliance

Yukiko Kimura, MD, & Laura E. Schanberg, MD  |  

Pediatric rheumatology was formally recognized as a specialty in 1991 by the American Board of Pediatrics. Prior to this time, children with rheumatic diseases were treated by a hodgepodge of providers. In addition to providers who had training as pediatric rheumatologists, general pediatricians, adult rheumatologists, allergist-immunologists, orthopedists, pediatric infectious disease specialists and others treated children…

Fecal Metabolomics Implicate Tryptophan Pathway in Pediatric Spondyloarthritis

  |  

Using metabolomic profiling of fecal samples of children with enthesitis-related arthritis (ERA), researchers found that children with ERA may have lower levels of tryptophan metabolites. This finding may be attributable to differences in the gut microbiota that contribute to their pro-inflammatory phenotype…

State-of-the-Art Course on Interprofessional Management of Rheumatoid Arthritis

  |  

During an interactive, case-based course at the 2016 ACR/ARHP Annual Meeting, participants will develop strategies to help patients manage unique barriers to access to care and adherence…

garagestock/shutterstock.com

E-Health, Telemedicine Pose Challenges, Offer Benefits for Patients with Arthritis

Michelle Burda, MLS, & Terence Starz, MD  |  

A 52-year-old woman comes to the office complaining of a two-month history of pain and swelling in the small joints of her hands, feet and knees. She says, “Doctor, I’ve been searching the Internet, and I think I have rheumatoid arthritis. I have some questions for you.” The healthcare system in the U.S. is changing…

2015 Treatment Recommendations for Psoriatic Arthritis

  |  

Psoriatic arthritis (PsA) is remarkably diverse in presentation and course. To assist clinicians in its management, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) published treatment recommendations in 2009 based on a systematic evidence review. To be clinically relevant, such recommendations must be dynamic, and significant developments in PsA pathophysiology and disease assessment, particularly regarding the important contribution of comorbidities coupled with major therapeutic advances, necessitated an update of the GRAPPA recommendations…

Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium

  |  

Therapy with tumor necrosis factor inhibitors, nonsteroidal antiinflammatory drugs, ustekinumab in early stages of osteitis may halt molecular switching to bone-forming phenotype characteristic of SpA